|Traded as||Euronext: OME|
|Marc Coucke (CEO), Lucas Laureys (Chairman)|
|Products||Prescription-free medicines and healthcare products|
|Revenue||€878.7 million (2010)|
|€107.5 million (2010)|
|Profit||€69.5 million (2010)|
|Total assets||€1.443 billion (end 2010)|
|Total equity||€718.3 million (end 2010)|
Number of employees
|2,130 (end 2010)|
At the occasion of the annual shareholders meeting of June 6, 2006; Omega Pharma announced the name under which its Professional Health division will henceforward operate: Arseus. Simultaneously, the management team of Arseus was presented. The legal structure of the entities in this division has been largely prepared in the mean time, so that the project to make Arseus an autonomous company is on schedule. Arseus became effectively an independent entity via an IPO on October 5, 2007 and has been listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam since then.
- "Annual Report 2010". Omega Pharma. Retrieved 22 April 2011.
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|
- "Perrigo to buy Belgium's Omega Pharma for $3.11 billion". Thomson Reuters. Reuters.